Drugs / JMT202
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06564467 | Jul 2024 → Jan 2025 overdue | — | Shanghai JMT-Bio Inc. | Enrolling by invitation | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07140809 | Sep 2025 → Jul 2026 overdue | hypertriglyceridemia | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-05-02 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - JMT202 (RECOMBINANT FULLY HUMAN ANTI-BETA KLOTHO MONOCLONAL ANTIBODY DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2024-05-17 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-Beta Klotho MONOCLONAL ANTIBODY DRUG (JMT202) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-02 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - JMT202 (RECOMBINANT FULLY HUMAN ANTI-BETA KLOTHO MONOCLONAL ANTIBODY DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2024-05-17 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-Beta Klotho MONOCLONAL ANTIBODY DRUG (JMT202) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JMT202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07140809 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT06564467 ↗ |